Clinical Trials | December 08, 2025
Pfizer’s therapy scores major win in Phase 3 trial for Hemophilia patients with inhibitors
HYMPAVZI’s safety profile was generally favorable
HYMPAVZI’s safety profile was generally favorable
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
76 of 180 long COVID-associated genes also linked to ME
The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
MRI is particularly valuable in pediatric care due to its non-invasive nature
The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population
Terray and BMS aim to accelerate small molecule drug discovery by harnessing EMMI’s integrated experimental and AI capabilities
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
The company is excluding data from the affected sites to maintain the study's integrity
Subscribe To Our Newsletter & Stay Updated
